ArticleBlood cancer journal2017
In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL.
S Laukkanen et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
20 papers cite it
this papercites it
ArticleBlood cancer journal2017
S Laukkanen et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.